Implications of Monoclonal Antibody Therapeutics Use for Clinical Laboratory Testing.

BACKGROUND: Monoclonal antibody therapeutics (MATs) represent a rapidly expanding class of biological drugs used to treat a variety of diseases. The widespread use of MATs increasingly affects clinical laboratory medicine. CONTENT: This review provides an overview of MATs currently approved for clin...

Descripción completa

Detalles Bibliográficos
Publicado en:Clinical Chemistry Vol. 65; no. 3; pp. 393 - 406
Autores principales: Lázár-Molnár, Eszter, Delgado, Julio C.
Formato: Journal Article
Publicado: Oxford University Press / USA Mar2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135074425&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 135074425
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00099147
        10CS
      jtl: Clinical Chemistry
      issn: 00099147
      maglogo: N
    pubinfo:
      dt: Mar2019
      vid: 65
      iid: 3
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        135074425
        10.1373/clinchem.2016.266973
        135074425
      ppf: 393
      ppct: 13
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Implications of Monoclonal Antibody Therapeutics Use for Clinical Laboratory Testing.
      aug:
        au:
          Lázár-Molnár, Eszter
          Delgado, Julio C.
        affil: ARUP Laboratories, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT
      sug:
      ab: BACKGROUND: Monoclonal antibody therapeutics (MATs) represent a rapidly expanding class of biological drugs used to treat a variety of diseases. The widespread use of MATs increasingly affects clinical laboratory medicine. CONTENT: This review provides an overview of MATs currently approved for clinical use in the US, starting from basic biology of antibodies to the engineering, pharmacokinetic and pharmacodynamic properties, nomenclature, and production of MATs. Immunogenicity and the production of antidrug antibodies (ADAs) play a major role in loss of therapeutic response and the development of treatment failure to certain MATs. Laboratory-based monitoring for MATs and detection of ADAs represent emerging needs for optimizing the use of MATs to achieve the best outcomes at affordable cost. In addition, the increased use of MATs affects clinical laboratory testing by interference of MATs with clinical laboratory tests across different areas of laboratory medicine, including histocompatibility, blood bank, and monoclonal protein testing. SUMMARY: The number of MATs is rapidly growing each year to address previously unmet clinical needs. Laboratory monitoring of MATs and detecting ADAs represent expanding areas of laboratory testing. Test-based strategies allow for treatment optimization at the level of the individual patient, thus providing a personalized medicine approach. In addition, clinical laboratories must be aware that the increasing use of MATs affects laboratory testing and be ready to implement methods to eliminate or mitigate interference with clinical tests.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N